Rosen Law Firm said it is investigating potential securities claims on behalf of Disc Medicine shareholders after the FDA (U.S. drug regulator) issued a Complete Response Letter on February 13, 2026, saying it could not approve the company’s new drug application for bitopertin because additional evidence was needed. Disc Medicine’s stock fell 22% that day. The firm is preparing a class action seeking recovery of investor losses and said eligible investors may participate through a contingency-fee arrangement without upfront fees or costs. Investors can submit information online or contact Phillip Kim, Esq.